Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ACON US Equity

Aclarion, Inc.Health Care · Services-Medical Laboratories · CIK 1635077 · FY ends Dec 31
$2.60
-0.17 (-6.14%)
USD · as of 2026-08-18 · marketstack
1 registered study · 1 active

Studies where ACON is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 observational

Held by 1 tracked-famous manager (SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
Examination of Nociscan Impact on Discogenic Low Back Pain Surgical OutcomesNCT06661850observationalChange in back pain on 100mm Visual Analog Scale (VAS) Pain AssessmentRecruitingProcedure: Fusion or TDR determined by investigator.Discogenic Low Back Pain3002027-09-30in 407 d2026-07-24

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19